What's new

RSS
Date Content
17/01/2019 Opinion/decision on a Paediatric investigation plan (PIP): 3-(3-(3,5-Dimethyl-1H-pyrazol-4-yl)propoxy)-4-fluorobenzoic acid, W: decision granting a waiver in all age groups for all conditions/indications, P/0330/2018
17/01/2019 Human medicines European public assessment report (EPAR): eribulin, Halaven, eribulin, Breast Neoplasms, Liposarcoma, 17/03/2011, 18, Authorised (updated)
17/01/2019 Opinion/decision on a Paediatric investigation plan (PIP): Telisotuzumab vedotin, W: decision granting a waiver in all age groups for all conditions/indications, P/0331/2018
17/01/2019 Human medicines European public assessment report (EPAR): pomalidomide, Imnovid (previously Pomalidomide Celgene), pomalidomide, Multiple Myeloma, 04/08/2013, 14, Authorised (updated)
17/01/2019 Opinion/decision on a Paediatric investigation plan (PIP): Irbesartan / amlodipine, W: decision granting a waiver in all age groups for all conditions/indications, P/0245/2018
17/01/2019 Human medicines European public assessment report (EPAR): palonosetron, Palonosetron Hospira, palonosetron, Nausea, Vomiting, Cancer, 08/04/2016, 4, Authorised (updated)
17/01/2019 Opinion/decision on a Paediatric investigation plan (PIP): Tepotinib, W: decision granting a waiver in all age groups for all conditions/indications, P/0279/2018
17/01/2019 Opinion/decision on a Paediatric investigation plan (PIP): Ianalumab, W: decision granting a waiver in all age groups for all conditions/indications, P/0332/2018
17/01/2019 Opinion/decision on a Paediatric investigation plan (PIP): Autologous T cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3- zeta chimeric antigen receptor, W: decision granting a waiver in all age groups for all conditions/indications, P/0232/2018
17/01/2019 Procurement activities 2018 (updated)